$512 Billion is the total value of Exane Asset Management's 114 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BAC | BANK AMER CORP COMstock | $12,670,000,000 | +4.5% | 500,000 | 0.0% | 2.48% | -34.5% | |
| C | CITIGROUP INC COM NEWstock | $9,092,500,000 | +8.8% | 125,000 | 0.0% | 1.78% | -31.8% | |
| DBVT | DBV TECHNOLOGIES S A SPONSORED ADRstock | $6,068,920,000 | +18.8% | 143,000 | 0.0% | 1.19% | -25.5% | |
| LMOS | LUMOS NETWORKS CORP COMstock | $543,406,000 | +0.3% | 30,324 | 0.0% | 0.11% | -37.3% | |
| XCRA | XCERRA CORP COMstock | $25,965,000 | +0.8% | 2,636 | 0.0% | 0.01% | -37.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-10-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UBS GROUP AG SHS | 25 | Q1 2023 | 31.8% |
| T-MOBILE US INC COM | 25 | Q3 2023 | 23.9% |
| GOLDMAN SACHS GROUP INC COM | 16 | Q3 2023 | 14.3% |
| BRISTOL-MYERS SQUIBB CO COM | 15 | Q1 2020 | 9.9% |
| CITIGROUP INC COM NEW | 15 | Q4 2022 | 18.8% |
| GILEAD SCIENCES INC COM | 15 | Q2 2019 | 8.9% |
| DBV TECHNOLOGIES S A SPONSORED ADR | 13 | Q2 2019 | 1.7% |
| CYTOMX THERAPEUTICS INC COM | 13 | Q4 2020 | 1.3% |
| MICROSOFT CORP COM | 12 | Q4 2022 | 19.4% |
| TIM PARTICIPACOES S A SPONSORED ADR | 12 | Q3 2019 | 12.2% |
View Exane Asset Management's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-23 |
| 13F-HR | 2024-01-24 |
| 13F-HR | 2023-10-20 |
| 13F-HR | 2023-07-17 |
| 13F-HR/A | 2023-05-11 |
| 13F-HR | 2023-04-25 |
| 13F-HR | 2023-01-17 |
| 13F-HR | 2022-10-24 |
| 13F-HR | 2022-07-15 |
| 13F-HR | 2022-04-21 |
View Exane Asset Management's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.